Insider Selling: Tyra Biosciences (NASDAQ:TYRA) Director Sells 14,295 Shares of Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Gilla Kaplan sold 14,295 shares of the firm’s stock in a transaction on Wednesday, March 25th. The stock was sold at an average price of $36.97, for a total value of $528,486.15. Following the completion of the transaction, the director directly owned 28,231 shares in the company, valued at approximately $1,043,700.07. This represents a 33.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Tyra Biosciences Stock Performance

NASDAQ:TYRA opened at $36.29 on Friday. The stock has a 50-day simple moving average of $32.90 and a two-hundred day simple moving average of $23.68. The firm has a market capitalization of $1.95 billion, a PE ratio of -18.05 and a beta of 1.06. Tyra Biosciences, Inc. has a 52-week low of $6.42 and a 52-week high of $39.15.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.03). Equities analysts forecast that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Institutional Trading of Tyra Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in TYRA. HighVista Strategies LLC boosted its stake in Tyra Biosciences by 163.6% in the 3rd quarter. HighVista Strategies LLC now owns 65,812 shares of the company’s stock worth $921,000 after purchasing an additional 40,850 shares during the period. Commodore Capital LP raised its position in shares of Tyra Biosciences by 8.9% during the third quarter. Commodore Capital LP now owns 3,375,000 shares of the company’s stock valued at $47,216,000 after buying an additional 275,000 shares during the last quarter. Boothbay Fund Management LLC bought a new stake in shares of Tyra Biosciences during the third quarter valued at approximately $2,612,000. Sio Capital Management LLC lifted its holdings in shares of Tyra Biosciences by 94.5% in the second quarter. Sio Capital Management LLC now owns 810,274 shares of the company’s stock worth $7,754,000 after buying an additional 393,657 shares in the last quarter. Finally, Walleye Capital LLC lifted its holdings in shares of Tyra Biosciences by 163.2% in the second quarter. Walleye Capital LLC now owns 370,408 shares of the company’s stock worth $3,545,000 after buying an additional 229,666 shares in the last quarter. Institutional investors own 84.14% of the company’s stock.

Analysts Set New Price Targets

TYRA has been the topic of a number of recent analyst reports. HC Wainwright raised their target price on shares of Tyra Biosciences from $30.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th. Barclays assumed coverage on shares of Tyra Biosciences in a research report on Tuesday, January 27th. They issued an “overweight” rating for the company. William Blair initiated coverage on shares of Tyra Biosciences in a research note on Tuesday, February 10th. They issued an “outperform” rating for the company. Piper Sandler raised their price objective on shares of Tyra Biosciences from $42.00 to $56.00 and gave the company an “overweight” rating in a research report on Friday, March 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $44.67.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.